MiMedx Group

Historical price data

MiMedx Group is a vertically integrated biopharmaceutical company focused on developing, processing, and commercializing regenerative placental tissue allografts for advanced wound care and surgical applications. Its core competitive advantage is the proprietary PURION® processing platform, which preserves the biological integrity of the tissue to create a diverse portfolio of products. The company has achieved significant commercial traction with over three million allografts distributed and payer coverage for over 300 million lives, positioning it as a leader in the placental biologics space. MiMedx's strategy centers on expanding its clinical evidence, penetrating existing markets, and exploring new surgical indications to drive growth.

Proprietary PURION® processing technology for human placental tissue, designed to gently cleanse, dehydrate, and terminally sterilize allografts while preserving the native extracellular matrix and biological proteins.

MiMedx competes with other placental tissue processors (e.g., Organogenesis), xenograft and ECM-based product companies, and living cell therapies. Its differentiation is based on its PURION® processing method, clinical evidence portfolio, and integrated commercial model with deep reimbursement expertise.